OPTOMED Optomed Oyj
Optomed Oyj, together with its subsidiaries, manufactures and sells handheld fundus cameras in Finland, rest of Europe, and internationally. The company operates in two segments, Devices and Software. It develops, manufactures, and sells fundus cameras for ophthalmologists, pediatricians, endocrinologists, neurologists, and primary health care professionals; and provides professional IT consulting services for government institutions. The company also provides camera products under the Optomed Smartscope Pro, Optomed Aurora, Optomed Aurora AEYE, Optomed Polaris, and Optomed Lumo brand names, as well as OEM cameras under the Volk Optical, Carl Zeiss Meditec, and Topcon brands. The company provides Avenue AI, an AI streamlines eye specialists' work and minimises screening costs; Avenue Eye Screen, a workflow management software for screening and monitoring of eye diseases; Avenue Flow, an eyecare management software; and Avenue Telemedicine, a remote analysis solution. In addition, it offers Cancer Screen, a screening process management software; Optomed Radiology Information System, a software solution for healthcare imaging units; Sectra PACS, a modular system for healthcare providers; Optomed Service Portal, a support function for healthcare units; Cephalometry, a powerful, flexible, and easy-to-use Windows software for orthodontics, oral and maxillofacial surgery; and Pathology PACS, which allows digital pathology images to be reviewed and shared. Optomed Oyj was incorporated in 2004 and is headquartered in Oulu, Finland.…
Industry Peers
Health Information ServicesKey Statistics
About Optomed (HEL: OPTOMED)
›
Optomed (HEL: OPTOMED) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 103 employees.
The shares were at 1.652 EUR on 19 November 2026, down 60.0% over 52 weeks. Its 52-week range is 1.322 EUR to 4.300 EUR: the price is 61.6% below the high and 25.0% above the low.
Its market capitalisation is 35.40M EUR.
Optomed reports return on equity of -27.6%, an operating margin of -24.4% and revenue up 17.5% year over year.
It holds more cash than debt, a net cash position of 4.62M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 2.267 EUR is 37.2% above the current price. The next earnings report is expected on 18 February 2027.